Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Type 1 selected

Type

Guidance programme

Showing 1 to 10 of 11

TitleTypeExpected publication date
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Technology appraisal guidanceTBC
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]Technology appraisal guidance
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897Technology appraisal guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All